TY - JOUR
T1 - Risk Factors for Malignant Progression to Adult-T-Cell Leukemia/Lymphoma in HTLV-1 Carriers
T2 - A Systematic Review of Cohort and Case-Control Studies
AU - Estrada-Grossmann, Jose M.
AU - Alarcón-Braga, Esteban A.
AU - Salazar-Valdivia, Farley E.
AU - Jauregui-Cornejo, Abigail S.
AU - Acurio, Karlos
AU - Pacheco-Barrios, Niels
AU - Al-kassab-Córdova, Ali
AU - Enriquez-Vera, Daniel
N1 - Publisher Copyright:
© 2025 Elsevier Inc.
PY - 2025/10
Y1 - 2025/10
N2 - Objective: To systematically evaluate and synthesize the existing evidence from cohort and case-control studies to identify risk factors associated with malignant progression to ATLL in HTLV-1 carriers. Methods: A systematic search was conducted in September 2023 in the following databases: Pubmed, Scopus, Web of Science, Medline and Embase. Only case-control and cohort studies that assessed the risk factors for the malignant progression to ATLL among HTLV-1 carriers in the adult population were included. The risk of bias was assessed through the Newcastle-Ottawa Scale. Meta-analysis was not performed due to high statistical and methodological heterogeneity. Results: After conducting a systematic search, 8170 results were retrieved, of which 9 (7 case-control and 2 cohort studies) met the selection criteria. Seven of them were conducted in Japan and six had low risk of bias. Serum sIL-2R levels, proviral load (PVL), cigarette consumption, Scd30 and TNF-α-857T allele were associated with an increased risk of ATLL progression. Conclusion: PVL emerges as the foremost recommended biomarker for predicting progression in patients with HTLV-1 associated ATLL. Further studies with larger samples sizes, different populations, more rigorous statistical adjustments, and longer follow-up are warranted.
AB - Objective: To systematically evaluate and synthesize the existing evidence from cohort and case-control studies to identify risk factors associated with malignant progression to ATLL in HTLV-1 carriers. Methods: A systematic search was conducted in September 2023 in the following databases: Pubmed, Scopus, Web of Science, Medline and Embase. Only case-control and cohort studies that assessed the risk factors for the malignant progression to ATLL among HTLV-1 carriers in the adult population were included. The risk of bias was assessed through the Newcastle-Ottawa Scale. Meta-analysis was not performed due to high statistical and methodological heterogeneity. Results: After conducting a systematic search, 8170 results were retrieved, of which 9 (7 case-control and 2 cohort studies) met the selection criteria. Seven of them were conducted in Japan and six had low risk of bias. Serum sIL-2R levels, proviral load (PVL), cigarette consumption, Scd30 and TNF-α-857T allele were associated with an increased risk of ATLL progression. Conclusion: PVL emerges as the foremost recommended biomarker for predicting progression in patients with HTLV-1 associated ATLL. Further studies with larger samples sizes, different populations, more rigorous statistical adjustments, and longer follow-up are warranted.
KW - Disease progression
KW - Oncogenic virus
KW - Prognostic biomarkers
KW - Retrovirus
KW - T-cell malignancy
UR - https://www.scopus.com/pages/publications/105005503057
U2 - 10.1016/j.clml.2025.04.013
DO - 10.1016/j.clml.2025.04.013
M3 - Artículo de revisión
C2 - 40393837
AN - SCOPUS:105005503057
SN - 2152-2650
VL - 25
SP - 720-729.e2
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 10
ER -